The Emerging Role of Novel GLP-1 RAs in the Management of T2DM: Assessing the Rationale and Evidence

The recent advances in the management of type 2 diabetes mellitus (T2DM) have significantly changed the treatment paradigm, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important part of this paradigm shift. They have emerged as a highly effective option for T2DM, demonstrating robust glucose-lowering effects with the additional benefits of low risk for hypoglycemia, weight loss, and improved cardiovascular outcomes. Furthermore, new and novel GLP-1 RAs have the potential to increase the utility of this class. Given the rapid advances in this field, clinicians may sometimes feel puzzled about how to best use the various T2DM agents, including existing and novel GLP-1 RAs, to maximize patient outcomes. In this webinar, experts will focus on the efficacy, safety, and the potential role existing and new GLP-1 RAs in the management of T2DM. In addition, the activity will overview the current T2DM treatment landscape in order to better convey ongoing treatment gaps and how emerging GLP-1 RAs can help address them.

The Emerging Role of Novel GLP-1 RAs in the Management of T2DM

Presenters: Vanita R. Aroda, MDKathleen M. Dungan, MD, MPH